



FY2024 Full Year  
Earnings Results

# FY2024 Earnings Results

---

Core Revenue

**¥4,579.8B**



**+2.8%**

Growth at Constant  
Exchange Rate (CER)




**+7.4%**

Growth at Actual  
Exchange Rate (AER)

# FY2024 Earnings Results - Growth Drivers

---

**Growth & Launch Products** continue their strong momentum, more than offsetting generic impact



# FY2024 Earnings Results

---

Core Operating Profit

**¥1,162.6B**

+4.9% growth at CER and  
+10.2% at AER.

Efficiency program driving  
cost savings

Core Operating Profit  
Margin

**25.4%**

Increased +0.6pp vs FY2023


Reported Operating Profit

**¥342.6B**

Growth in Core Operating  
Profit and lower impairment of  
intangible assets compared to  
FY2023

# Progress in Late-Stage Pipeline

---



# FY2025 Full Year Outlook

---

Continued momentum of Growth & Launch Products while preparing for new product launches from late-stage pipeline

Core Revenue

**¥4,530.0B**

Core Operating Profit

**¥1,140.0B**

Core EPS

**¥485**

## Management Guidance at CER

**Core Revenue**

Broadly flat

**Core Operating Profit**


Broadly flat

**Core EPS**

Broadly flat


# Committed to Growth & Shareholder Returns

Delivering sustainable value to patients and attractive returns to shareholders, supported by our balance sheet (maintaining solid investment grade credit ratings; targeting 2x adjusted net debt / adjusted EBITDA)




# FY2024 Capital Allocation

## Invest in Growth Drivers



## Shareholder Returns



\*Completed share buyback in April 2025. Total approx. JPY100 billion





This presentation contains forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations. For more information about our use of forward-looking statements, including important cautionary language, see Takeda's FY2024 investor presentation (available at <https://www.takeda.com/investors/financial-results/quarterly-results/>), which is hereby incorporated by reference. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

CER (Constant Exchange Rate) change eliminates the effect of foreign exchange rates from year-over-year comparisons by translating financial results in accordance with IFRS or Core (non-IFRS) financial measures for the current period using corresponding exchange rates in the same period of the previous fiscal year.

Core Revenue, Core Operating Profit, Core Net Profit for the year attributable to owners of the Company, Core EPS, Constant Exchange Rate ("CER") change, Net Debt, Adjusted Net Debt, EBITDA, Adjusted EBITDA, Free Cash Flow and Adjusted Free Cash Flow are Non-IFRS measures, i.e., measures not calculated and presented in accordance with IFRS. See the financial appendix at the end of Takeda's FY2024 investor presentation (available at <https://www.takeda.com/investors/financial-results/quarterly-results/>) for further information about Takeda's Non-IFRS Measures and reconciliations to the most directly comparable measures calculated and presented in accordance with IFRS.